Published in PLoS One on July 05, 2012
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis. Medicine (Baltimore) (2014) 0.83
Regulatory Variants and Disease: The E-Cadherin -160C/A SNP as an Example. Mol Biol Int (2014) 0.80
miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. Front Pharmacol (2016) 0.77
Risk prediction for early-onset gastric carcinoma: a case-control study of polygenic gastric cancer in Han Chinese with hereditary background. Oncotarget (2016) 0.76
Single nucleotide variants in metastasis-related genes are associated with breast cancer risk, by lymph node involvement and estrogen receptor status, in women with European and African ancestry. Mol Carcinog (2016) 0.75
The CDH1 -160C/A polymorphism is associated with breast cancer: evidence from a meta-analysis. World J Surg Oncol (2016) 0.75
Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan. PLoS One (2013) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
A tutorial on statistical methods for population association studies. Nat Rev Genet (2006) 12.49
Controlling the risk of spurious findings from meta-regression. Stat Med (2004) 6.80
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med (2006) 5.43
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 4.15
Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol (2003) 2.14
A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res (2000) 1.70
Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer (2002) 1.58
The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol (2006) 1.43
A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci U S A (2009) 1.33
CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer (2002) 1.13
Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene (2002) 1.13
Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res (2008) 1.11
The E-cadherin gene polymorphism 160C->A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol (2007) 1.05
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene (2002) 1.04
Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One (2009) 1.00
The E-cadherin -347G->GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis (2004) 0.98
Association of the -160 C --> a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer (2002) 0.98
Functional analysis and case-control study of -160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. Anticancer Res (2007) 0.97
Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res (2002) 0.96
A functional polymorphism (-347 G-->GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis (2004) 0.95
Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis (2007) 0.95
Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. World J Gastroenterol (2010) 0.93
Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility. J Biomed Sci (2006) 0.93
The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. Int J Cancer (2008) 0.92
The CDH1-160C>A polymorphism is a risk factor for colorectal cancer. Int J Cancer (2009) 0.91
CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer (2002) 0.90
Association between CDH1 haplotypes and gastric cancer risk in a Japanese population. Scand J Gastroenterol (2007) 0.88
E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett (2003) 0.88
Varicocele-induced testicular dysfunction may be associated with disruption of blood-testis barrier. Arch Androl (2007) 0.88
CDH1 C-160A promoter polymorphism and gastric cancer risk. Eur J Cancer Prev (2009) 0.88
Genetic polymorphisms of the E-cadherin promoter and risk of sporadic gastric carcinoma in Chinese populations. Cancer Epidemiol Biomarkers Prev (2008) 0.87
DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int (2007) 0.87
Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int J Oncol (2003) 0.87
-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer (2004) 0.87
Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Lung Cancer (2008) 0.86
E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate (2006) 0.86
Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population. Ann Surg Oncol (2007) 0.86
A single nucleotide polymorphism in the E-cadherin gene promoter-160 is not associated with risk of Korean gastric cancer. J Korean Med Sci (2003) 0.86
Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. J Surg Oncol (2011) 0.86
Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet (2005) 0.85
E-cadherin gene C-160A promoter polymorphism and risk of non-cardia gastric cancer in a Chinese population. World J Gastroenterol (2005) 0.85
CDH1 gene polymorphisms, smoking, Helicobacter pylori infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Eur J Cancer (2008) 0.85
Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population. Endocrine (2011) 0.84
Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int (2004) 0.83
[Association of -160(C-->A) polymorphism in CDH1 gene with gastric cancer risk in Fujian Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2005) 0.83
E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese. Gynecol Oncol (2007) 0.82
[Correlation of E-cadherin polymorphisms to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. Ai Zheng (2005) 0.82
Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol (2003) 0.81
Polymorphisms in the 3'-untranslated region of the CDH1 gene are a risk factor for primary gastric diffuse large B-cell lymphoma. Haematologica (2011) 0.81
Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population. Urology (2007) 0.80
Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines. Pharmacogenet Genomics (2010) 0.80
Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. Eur J Cancer (2006) 0.80
E-cadherin polymorphism--160 C/A and prostate cancer. Int J Cancer (2004) 0.80
Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn J Clin Oncol (2005) 0.80
A single nucleotide polymorphism in the E-cadherin gene promoter -160 C/A is associated with risk of nasopharyngeal cancer. Clin Chim Acta (2010) 0.78
DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder. BJU Int (2008) 0.77
Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathologic development of oral cancer. Head Neck (2011) 0.77
E-cadherin-160 C/A promoter polymorphism and risk of pancreatic carcinoma in Chinese population. Cancer Genet Cytogenet (2010) 0.76
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature (2010) 3.84
MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol (2009) 3.48
The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell (2010) 2.89
Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell (2013) 2.77
Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. Cell Res (2008) 2.29
Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature (2009) 2.27
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res (2012) 2.18
Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat Immunol (2007) 2.15
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril (2002) 2.10
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells (2010) 1.97
Calcium precursors for the production of CaO sorbents for multicycle CO2 capture. Environ Sci Technol (2010) 1.52
Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res (2011) 1.47
Possible role of the 'IDO-AhR axis' in maternal-foetal tolerance. Cell Biol Int (2013) 1.43
Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol (2011) 1.41
Laparoscopic treatment for small intestinal bleeding: a report of 77 cases. J Laparoendosc Adv Surg Tech A (2010) 1.38
Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res (2014) 1.34
Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2012) 1.29
Laparoscopic versus open right hemicolectomy with curative intent for colon carcinoma. World J Gastroenterol (2005) 1.28
Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J Med Chem (2012) 1.28
Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res (2009) 1.25
Critical regulation of miR-200/ZEB2 pathway in Oct4/Sox2-induced mesenchymal-to-epithelial transition and induced pluripotent stem cell generation. Proc Natl Acad Sci U S A (2013) 1.21
Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci (2011) 1.21
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem (2012) 1.19
Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res (2011) 1.18
Beta-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation. EMBO J (2005) 1.15
A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev (2013) 1.13
microRNA-29b is a novel mediator of Sox2 function in the regulation of somatic cell reprogramming. Cell Res (2012) 1.12
Physicochemical determinants of human renal clearance. J Med Chem (2009) 1.11
The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res (2009) 1.11
Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. Cell Res (2008) 1.10
Oncological superiority of extralevator abdominoperineal resection over conventional abdominoperineal resection: a meta-analysis. Int J Colorectal Dis (2014) 1.10
The role of bias in crystallization conditions in automated microseeding. Acta Crystallogr D Biol Crystallogr (2008) 1.08
Long isoforms of NRF1 contribute to arsenic-induced antioxidant response in human keratinocytes. Environ Health Perspect (2010) 1.07
Brain-derived neurotrophic factor: a novel human ovarian follicular protein. J Clin Endocrinol Metab (2002) 1.07
Beta-arrestin1 regulates zebrafish hematopoiesis through binding to YY1 and relieving polycomb group repression. Cell (2009) 1.07
Direct proof of the tree-level scattering amplitude recursion relation in Yang-mills theory. Phys Rev Lett (2005) 1.06
Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem (2013) 1.06
Metabonomics identifies serum metabolite markers of colorectal cancer. J Proteome Res (2013) 1.05
More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells. Cell Res (2009) 1.04
MiR-138 promotes induced pluripotent stem cell generation through the regulation of the p53 signaling. Stem Cells (2012) 1.04
Wide distribution among halophilic archaea of a novel polyhydroxyalkanoate synthase subtype with homology to bacterial type III synthases. Appl Environ Microbiol (2010) 1.02
Altered resting-state functional connectivity of thalamus in earthquake-induced posttraumatic stress disorder: a functional magnetic resonance imaging study. Brain Res (2011) 1.02
Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J Biol Chem (2013) 1.02
Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit (2012) 1.01
miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis (2013) 1.01
A PRC2-dependent repressive role of PRDM14 in human embryonic stem cells and induced pluripotent stem cell reprogramming. Stem Cells (2013) 1.01
A fluorescent rosamine compound selectively stains pluripotent stem cells. Angew Chem Int Ed Engl (2010) 1.01
Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci (2006) 0.99
The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos (2009) 0.99
Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2012) 0.98
Is yangxue qingnao granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension? Evid Based Complement Alternat Med (2013) 0.97
Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS One (2013) 0.96
Laparoscopic gastric resection approaches for gastrointestinal stromal tumors of stomach. Surg Laparosc Endosc Percutan Tech (2011) 0.96
Simultaneous laparoscopy-assisted low anterior resection and distal gastrectomy for synchronous carcinoma of rectum and stomach. World J Gastroenterol (2008) 0.96
Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2013) 0.95
P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol (2010) 0.95
The metastasis suppressor, N-myc downregulated gene 1 (NDRG1), is a prognostic biomarker for human colorectal cancer. PLoS One (2013) 0.95
Immunocytochemical evidence for the presence and location of the neurotrophin-Trk receptor family in adult human preovulatory ovarian follicles. Am J Obstet Gynecol (2006) 0.95
Effect of chlorpyrifos on soil microbial populations and enzyme activities. J Environ Sci (China) (2006) 0.95
Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression. Pharmazie (2011) 0.94
Zhen gan xi feng decoction, a traditional chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2013) 0.94
Cardiovascular effects of salvianolic Acid B. Evid Based Complement Alternat Med (2013) 0.94
Retinoic acid regulates germ cell differentiation in mouse embryonic stem cells through a Smad-dependent pathway. Biochem Biophys Res Commun (2012) 0.93
VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol Cell Biochem (2011) 0.93
Lynx: a database and knowledge extraction engine for integrative medicine. Nucleic Acids Res (2013) 0.93
Laparoscopic low anterior resection for rectal carcinoma: complications and management in 132 consecutive patients. World J Gastroenterol (2010) 0.93
Insights into the coupling of duplication events and macroevolution from an age profile of animal transmembrane gene families. PLoS Comput Biol (2006) 0.92
Tai chi for essential hypertension. Evid Based Complement Alternat Med (2013) 0.92
Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease. J Biomed Biotechnol (2012) 0.91
Long-term results of laparoscopy-assisted radical right hemicolectomy with D3 lymphadenectomy: clinical analysis with 177 cases. Int J Colorectal Dis (2012) 0.91
Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells. Exp Ther Med (2013) 0.90
Clinical application of interventional techniques in the treatment of Budd-Chiari syndrome. Chin Med J (Engl) (2003) 0.90
Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. DNA Cell Biol (2011) 0.90
Long-term outcome of laparoscopic-assisted right-hemicolectomy with D3 lymphadenectomy versus open surgery for colon carcinoma. Surg Today (2013) 0.90
Water-soluble antioxidants improve the antioxidant and anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie (2005) 0.90
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm (2010) 0.89
P21-activated protein kinase 1 is overexpressed in gastric cancer and induces cancer metastasis. Oncol Rep (2012) 0.89
Learning curve and long-term outcomes of laparoscopy-assisted distal gastrectomy for gastric cancer. J Laparoendosc Adv Surg Tech A (2014) 0.88
Impacts of yeast metabolic network structure on enzyme evolution. Genome Biol (2007) 0.88
Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116. World J Gastroenterol (2009) 0.88
Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol (2012) 0.88
Medicinal chemistry design principles for liver targeting through OATP transporters. Curr Top Med Chem (2013) 0.88
A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos (2013) 0.88
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. Mol Cancer Res (2012) 0.88
Altered regional homogeneity in post-traumatic stress disorder: a resting-state functional magnetic resonance imaging study. Neurosci Bull (2012) 0.88
Degradation of chlorpyrifos alone and in combination with chlorothalonil and their effects on soil microbial populations. J Environ Sci (China) (2008) 0.88
Haloarchaeal-type β-ketothiolases involved in Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) synthesis in Haloferax mediterranei. Appl Environ Microbiol (2013) 0.88
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm (2011) 0.87
Decreased expression of WWOX in the development of esophageal squamous cell carcinoma. Mol Carcinog (2011) 0.87
The functions of microRNAs and long non-coding RNAs in embryonic and induced pluripotent stem cells. Genomics Proteomics Bioinformatics (2013) 0.87
Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Lung Cancer (2008) 0.86